Medicare coverage for all localized prostate cancer patients
Medicare coverage for all localized prostate cancer patients
Decipher is covered by Medicare for all patients with localized or regional prostate cancer being considered for treatment, including patients at diagnosis and patients after surgery with undetectable, persistent, or rising PSA.
Decipher Genomic Risk is Determined by Tumor Biology Alone,
Independent of Clinical Information
Decipher Genomic Risk is Determined by Tumor Biology Alone,
Independent of Clinical Information
Independent of Clinical Information
Decipher is the only prostate cancer test that provides a genomic risk score that is completely independent of already known clinical and pathological information.
References
References
1. Vince Jr, RA et al. Prostate Cancer Prostatic Dis (2021).
2. Kim, HL et al. Prostate Cancer Prostatic Dis 22, 399-405 (2019).
3. Herlemann, A et al. Prostate Cancer Prostatic Dis 23, 136-143 (2020).
4. Berlin, A et al. Int J Radiat Oncol Biol Phys 103, 84-91 (2019).
5. Spratt, DE et al. J Clin Oncol 36, 581-590 (2018).
6. NCCN Guidelines® for Prostate Cancer v1.2023*
7. Spratt, D. E. et al. J Clin Oncol 40, 269-269 (2022).
8. Nguyen, PL et al. Prostate Cancer Prostatic Dis 20, 186-192 (2017).
9. Nguyen, PL et al. Int J Radiat Oncol BIol Phys (2023).
10. Den, RB et al. J Clin Oncol 33, 944-951 (2015).
11. Ross, AE et al. Prostate Cancer Prostatic Dis 19, 277-282 (2016).
12. Marascio, J et al. Prostate Cancer Prostatic Dis (2019).
13. Feng, FY et al. JAMA Oncol 7(4): 544-552 (2021).
14. Spratt, DE et al. Eur Urol 74, 107-114 (2018).
15. Dal Pra A et al., Ann Oncol, 33(9); 950-958 (2022).